December 17, 2020

Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO

2021-09-09T12:54:42-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company’) (TSXV: APC) (FSE: 0E8), is pleased to announce that Dr. Benjamin Krantz will be joining the Company’s US subsidiary Advanced Proteome Therapeutics Inc. (“APTI”) as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board of directors after.

Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO2021-09-09T12:54:42-04:00
December 10, 2020

Advanced Proteome Therapeutics Provides Antibody Radioisotope Conjugate Project Update

2021-09-09T12:49:30-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is providing an update on its radioimaging and biodistribution study.

Advanced Proteome Therapeutics Provides Antibody Radioisotope Conjugate Project Update2021-09-09T12:49:30-04:00
December 3, 2020

Advanced Proteome Therapeutics Announces Options Grants and Cancelations

2021-09-09T12:57:31-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), announces that it has granted 1,575,000 incentive stock options to directors, officers, and consultants. The incentive stock options have an exercise price of $0.11 per share, are valid for a 2-year period from the date of grant, and are subject to regulatory approval.

Advanced Proteome Therapeutics Announces Options Grants and Cancelations2021-09-09T12:57:31-04:00
Go to Top